

SUMMARY OF PRODUCT CHARACTERISTICS

1. Name of the medicinal product

SANZIDIME - 1000

Ceftazidime for Injection USP 1000mg

2. Qualitative and quantitative composition

Label claim:

Each vial contains:

Sterile Ceftazidime pentahydrate buffered with sodium carbonate USP equivalent to anhydrous Ceftazidime 1000mg

Sr. No	Material	Specification	Quantity/Vial in mg	Function
1	Ceftazidime for injection	USP	1332.0*	Active Pharmaceutical Ingredient

Remarks:

* Standard quantity of Ceftazidime mentioned is based on 97.5 % w/w assay value of Ceftazidime on dried and sodium carbonate free basis; 9.5 % w/w of sodium carbonate and 13.5% water content.

3. Pharmaceutical form: Dry powder for Injection

Description: White or almost white crystalline powder, distributed in sealed containers and which, when shaken with the prescribed volume of the appropriate sterile liquid, rapidly form clear and practically particle-free solution.

4. Clinical particulars

4.1 Therapeutic indications

Ceftazidime for Injection is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).

- Nosocomial pneumonia
- Broncho-pulmonary infections in cystic fibrosis
- Bacterial meningitis
- Chronic suppurative otitis media
- Malignant otitis externa
- Complicated urinary tract infections
- Complicated skin and soft tissue infections
- Complicated intra-abdominal infections
- Bone and joint infections
- Peritonitis associated with dialysis in patient on CAPD.

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing transurethral resection of the prostate (TURP).

The selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic Gram negative bacteria.

Ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum of activity.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology

Table 1: Adults and children ≥ 40 kg

Intermittent Administration	
Infection	Dose to be administered
Broncho-pulmonary infections in cystic fibrosis	100 to 150 mg/kg/day every 8 h, maximum 9 g per day ₁
Febrile neutropenia	2 g every 8 h
Nosocomial pneumonia	
Bacterial meningitis	
Bacteraemia*	
Bone and joint infections	1-2 g every 8 h
Complicated skin and soft tissue infections	
Complicated intra-abdominal infections	
Peritonitis associated with dialysis in patients on CAPD	
Complicated urinary tract infections	1-2 g every 8 h or 12 h
Peri-operative prophylaxis for transurethral resection of prostate (TURP)	1 g at induction of anaesthesia, and a second dose at catheter removal
Chronic suppurative otitis media	1 g to 2 g every 8h
Malignant otitis externa	
Continuous Infusion	
Infection	Dose to be administered
Febrile neutropenia	Loading dose of 2 g followed by a continuous infusion of 4 to 6 g every 24 h ₁
Nosocomial pneumonia	
Broncho-pulmonary infections in cystic fibrosis	
Bacterial meningitis	
Bacteraemia*	
Bone and joint infections	
Complicated skin and soft tissue infections	
Complicated intra-abdominal infections	

Peritonitis associated with dialysis in patients on CAPD	
₁ In adults with normal renal function 9 g/day has been used without adverse effects. * When associated with, or suspected to be associated with, any of the infections listed	

Table 2: Children < 40 kg

Infants and toddlers >2 months and children < 40 kg	Infection	Usual dose	
Intermittent Administration			
	Complicated urinary tract infections	100-150 mg/kg/day in three divided doses, maximum 6 g/day	
	Chronic suppurative otitis media		
	Malignant otitis externa		
	Neutropenic children	150 mg/kg/day in three divided doses, maximum 6 g/day	
	Broncho-pulmonary infections in cystic fibrosis		
	Bacterial meningitis		
	Bacteraemia*		
	Bone and joint infections	100-150 mg/kg/day in three divided doses, maximum 6 g/day	
	Complicated skin and soft tissue infections		
	Complicated intra-abdominal infections		
	Peritonitis associated with dialysis in patients on CAPD		
	Continuous Infusion		
		Febrile neutropenia	Loading dose of 60-100 mg/kg followed by a continuous infusion 100-200 mg/kg/day, maximum 6 g/day
		Nosocomial pneumonia	
Broncho-pulmonary infections in cystic fibrosis			
Bacterial meningitis			
Bacteraemia*			
Bone and joint infections			
Complicated skin and soft tissue infections			
Complicated intra-abdominal infections			
Peritonitis associated with dialysis in patients on CAPD			
Neonates and infants ≤ 2 months	Infection	Usual dose	
Intermittent Administration			

	Most infections	25-60 mg/kg/day in two divided doses ₁
₁ In neonates and infants ≤ 2 months, the serum half life of ceftazidime can be three to four times that in adults. * Where associated with or suspected to be associated with any of the infections listed		

Paediatric population

The safety and efficacy of Ceftazidime administered as continuous infusion to neonates and infants ≤ 2 months has not been established.

Elderly

In view of age related reduced clearance of Ceftazidime in elderly patients, the daily dose should not normally exceed 3 g in those over 80 years of age.

Hepatic impairment

Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment. There are no study data in patients with severe hepatic impairment. Close clinical monitoring for safety and efficacy is advised.

Renal impairment

Ceftazidime is excreted unchanged by the kidneys. Therefore, in patients with impaired renal function, the dosage should be reduced.

An initial loading dose of 1 g should be given. Maintenance doses should be based on creatinine clearance:

Table 3: Recommended maintenance doses of Ceftazidime for Injection in renal impairment – intermittent infusion

A) Adults and children ≥ 40 kg

Creatinine clearance (ml/min)	Approx. serum creatinine μmol/l (mg/dl)	Recommended unit dose of Ceftazidime (g)	Frequency of dosing (hourly)
50-31	150-200 (1.7-2.3)	1	12
30-16	200-350 (2.3-4.0)	1	24
15-6	350-500 (4.0-5.6)	0.5	24
<5	>500 (>5.6)	0.5	48

In patients with severe infections the unit dose should be increased by 50% or the dosing frequency increased.

In children the creatinine clearance should be adjusted for body surface area or lean body mass.

B) Children < 40 kg

Creatinine clearance (ml/min)**	Approx. serum creatinine* $\mu\text{mol/l}$ (mg/dl)	Recommended individual dose mg/kg body weight	Frequency of dosing (hourly)
50-31	150-200 (1.7-2.3)	25	12
30-16	200-350 (2.3-4.0)	25	24
15-6	350-500 (4.0-5.6)	12.5	24
<5	>500 (>5.6)	12.5	48

* The serum creatinine values are guideline values that may not indicate exactly the same degree of reduction for all patients with reduced renal function.

** Estimated based on body surface area, or measured.

Close clinical monitoring for safety and efficacy is advised.

Table 4: Recommended maintenance doses of Ceftazidime in renal impairment – continuous infusion

A) Adults and children \geq 40 kg

Creatinine clearance (ml/min)	Approx. serum creatinine $\mu\text{mol/l}$ (mg/dl)	Frequency of dosing (hourly)
50-31	150-200 (1.7-2.3)	Loading dose of 2 g followed by 1 g to 3 g /24 hours
30-16	200-350 (2.3-4.0)	Loading dose of 2 g followed by 1 g/24 hours
\leq 15	>350 (>4.0)	Not evaluated

Caution is advised in dose selection. Close clinical monitoring for safety and efficacy is advised.

B) Children < 40 kg

The safety and effectiveness of Ceftazidime administered as continuous infusion in renally impaired children < 40 kg has not been established. Close clinical monitoring for safety and efficacy is advised.

If continuous infusion is used in children with renal impairment, the creatinine clearance should be adjusted for body surface area or lean body mass.

Haemodialysis

The serum half-life during haemodialysis ranges from 3 to 5 h.

Following each haemodialysis period, the maintenance dose of ceftazidime recommended in the below table should be repeated.

Peritoneal dialysis

Ceftazidime may be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD).

In addition to intravenous use, ceftazidime can be incorporated into the dialysis fluid (usually 125 to 250 mg for 2 litres of dialysis solution).

For patients in renal failure on continuous arterio-venous haemodialysis or high-flux haemofiltration in intensive therapy units: 1 g daily either as a single dose or in divided doses. For low-flux haemofiltration, follow the dose recommended under renal impairment.

For patients on veno-venous haemofiltration and veno-venous haemodialysis, follow the dosage recommendations in the tables below.

Table 5: Continuous veno-venous haemofiltration dose guidelines

Residual renal function (creatinine clearance ml/min)	Maintenance dose (mg) for an ultrafiltration rate (ml/min) of 1:			
	5	16.7	33.3	50
0	250	250	500	500
5	250	250	500	500
10	250	500	500	750
15	250	500	500	750
20	500	500	500	750

Maintenance dose to be administered every 12 h.

Table 6: Continuous veno-venous haemodialysis dose guidelines

Residual renal function (creatinine clearance in ml/min)	Maintenance dose (mg) for a dialysate in flow rate of 1:					
	1.0 litre/h			2.0 litre/h		
	Ultrafiltration rate (litre/h)			Ultrafiltration rate (litres/h)		
	0.5	1.0	2.0	0.5	1.0	2.0
0	500	500	500	500	500	750
5	500	500	750	500	500	750
10	500	500	750	500	750	1000
15	500	750	750	750	750	1000
20	750	750	1000	750	750	1000

Maintenance dose to be administered every 12 h.

Method of Administration

Ceftazidime should be administered by intravenous injection or infusion, or by deep intramuscular injection. Recommended intramuscular injection sites are the upper outer quadrant of the *gluteus maximus* or lateral part of the thigh. Ceftazidime solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids.

The standard recommended route of administration is by intravenous intermittent injection or intravenous continuous infusion. Intramuscular administration should only be considered when the intravenous route is not possible or less appropriate for the patient.

The dose depends on the severity, susceptibility, site and type of infection and on the age and renal function of the patient.

4.3 Contraindications

Hypersensitivity to ceftazidime, to any of the cephalosporins or to any of the excipients.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

4.4 Special warnings and precautions for use

Hypersensitivity

As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with ceftazidime must be discontinued immediately and adequate emergency measures must be initiated.

Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftazidime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Spectrum of activity

Ceftazidime has a limited spectrum of antibacterial activity. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a very high suspicion that the most likely pathogen(s) would be suitable for treatment with ceftazidime. This particularly applies when considering the treatment of patients with bacteraemia and when treating bacterial meningitis, skin and soft tissue infections and bone and joint infections. In addition, ceftazidime is susceptible to hydrolysis by several of the extended spectrum beta lactamases (ESBLs). Therefore information on the prevalence of ESBL producing organisms should be taken into account when selecting ceftazidime for treatment.

Pseudomembranous colitis

Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all anti-bacterial agents, including ceftazidime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftazidime (see section 4.8). Discontinuation of therapy with ceftazidime and the administration of specific treatment for

Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.

Renal function

Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function.

Ceftazidime is eliminated via the kidneys, therefore the dose should be reduced according to the degree of renal impairment. Patients with renal impairment should be closely monitored for both safety and efficacy. Neurological sequelae have occasionally been reported when the dose has not been reduced in patients with renal impairment (see section 4.2 and 4.8).

Overgrowth of non-susceptible organisms

Prolonged use may result in the overgrowth of non-susceptible organisms (e.g. Enterococci, fungi) which may require interruption of treatment or other appropriate measures. Repeated evaluation of the patient's condition is essential.

Test and assay interactions

Ceftazidime does not interfere with enzyme-based tests for glycosuria, but slight interference (false-positive) may occur with copper reduction methods (Benedict's, Fehling's, Clinitest).

Ceftazidime does not interfere in the alkaline picrate assay for creatinine.

The development of a positive Coombs' test associated with the use of ceftazidime in about 5% of patients may interfere with the cross-matching of blood.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been conducted with probenecid and furosemide.

Concurrent use of high doses with nephrotoxic medicinal products may adversely affect renal function.

Chloramphenicol is antagonistic *in vitro* with Ceftazixime and other cephalosporins. The clinical relevance of this finding is unknown, but if concurrent administration of ceftazidime with chloramphenicol is proposed, the possibility of antagonism should be considered.

4.6 Fertility, Pregnancy and lactation

Pregnancy

There are limited amounts of data from the use of ceftazidime in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy embryonal/foetal development, parturition or postnatal development.

Ceftazidime should be prescribed to pregnant woman only if the benefit outweighs the risk.

Breast Feeding

Ceftazidime is excreted in human milk in small quantities but at therapeutic doses of ceftazidime no effects on the breast-fed infant are anticipated. Ceftazidime can be used during breast-feeding.

Fertility

No data are available.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines.

4.8 Undesirable effects

The most common adverse reactions are eosinophilia, thrombocytosis, phlebitis or thrombophlebitis with intravenous administration, diarrhoea, transient increases in hepatic enzymes, maculopapular or urticarial rash, pain and/or inflammation following intramuscular injection and positive Coomb's test.

Data from sponsored and un-sponsored clinical trials have been used to determine the frequency of common and uncommon undesirable effects. The frequencies assigned to all other undesirable effects were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The following convention has been used for the classification of frequency:

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1,000$ to $< 1/100$)

Rare ($\geq 1/10,000$ to $< 1/1,000$)

Very rare ($< 1/10,000$)

Unknown (cannot be estimated from the available data)

<u>System Organ Class</u>	<u>Common</u>	<u>Uncommon</u>	<u>Very rare</u>	<u>Unknown</u>
<u>Infections and infestations</u>		Candidiasis (including vaginitis and oral thrush)		
<u>Blood and lymphatic system disorders</u>	Eosinophilia Thrombocytosis	Neutropenia Leucopenia Thrombocytopenia		Agranulocytosis Haemolytic anaemia Lymphocytosis
<u>Immune system disorders</u>				Anaphylaxis (including bronchospasm and/or hypotension)
<u>Nervous system disorders</u>		Headache Dizziness		Neurological sequelae ¹ Paraesthesia
<u>Vascular disorders</u>	Phlebitis or thrombophlebitis with intravenous administration			
<u>Gastrointestinal disorders</u>	Diarrhoea	Antibacterial agent-associated		Bad taste

		diarrhoea and colitis ² Abdominal pain Nausea Vomiting		
<u>Hepatobiliary disorders</u>	Transient elevations in one or more hepatic enzymes ³			Jaundice
<u>Skin and subcutaneous tissue disorders</u>	Maculopapular or urticarial rash	Pruritus		Toxic epidermal necrolysis Stevens-johnson syndrome Erythema multiforme Angioedema
<u>Renal and urinary disorders</u>		Transient elevations of blood urea, blood urea nitrogen and/or serum creatinine	Interstitial nephritis Acute renal failure	
<u>General disorders and administration site conditions</u>	Pain and/or inflammation after intramuscular injection	Fever		
<u>Investigations</u>	Positive Coombs' test ⁴			

¹There have been reports of neurological sequelae including tremor, myoclonia, convulsions, encephalopathy, and coma in patients with renal impairment in whom the dose of Ceftazidime has not been appropriately reduced.

² Diarrhoea and colitis may be associated with Clostridium difficile and may present as pseudomembranous colitis.

³ ALT (SGPT), AST (SOGT), LHD, GGT, alkaline phosphatase.

⁴ A positive Coombs test develops in about 5% of patients and may interfere with blood cross matching.

4.9 Overdose

Overdose can lead to neurological sequelae including encephalopathy, convulsion and coma.

Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment.

Serum levels of ceftazidime can be reduced by haemodialysis or peritoneal dialysis.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antibacterials for systemic use. Third-generation cephalosporins
ATC code : J01DD02.

Mechanism of action

Ceftazidime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

PK/PD relationship

For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with in vivo efficacy has been shown to be the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftazidime for individual target species (i.e. %T>MIC).

Mechanism of Resistance

Bacterial resistance to ceftazidime may be due to one or more of the following mechanisms:

- Hydrolysis by beta-lactamases. Ceftazidime may be efficiently hydrolysed by extended spectrum beta-lactamases (ESBLs), including the SHV family of ESBLs, and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species
- reduced affinity of penicillin-binding proteins for ceftazidime
- Outer membrane impermeability, which restricts access of ceftazidime to penicillin binding proteins in Gram-negative organisms.
- Bacterial efflux pumps.

Breakpoints

Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:

Organism	Breakpoints (mg/L)		
	S	I	R
Enterobacteriaceae	≤ 1	2-4	> 4
Pseudomonas aeruginosa	≤ 8 ₁	-	> 8
Non-species related breakpoints ₂	≤4	8	> 8

S=susceptible, I=intermediate, R=resistant.

₁The breakpoints relate to high dose therapy (2 g x 3).

₂Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species not mentioned in the table or footnotes.

Microbiological Susceptibility

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftazidime in at least some types of infections is questionable

Commonly Susceptible Species

Gram-positive aerobes:

Streptococcus pyogenes
Streptococcus agalactiae

Gram-negative aerobes:

Citrobacter koseri
Escherichia coli
Haemophilus influenzae
Moraxella catarrhalis
Neisseria meningitidis
Proteus mirabilis
Proteus spp. (other)
Providencia spp.

Species for which acquired resistance may be a problem

Gram-negative aerobes:

Acinetobacter baumannii£+
Burkholderia cepacia
Citrobacter freundii
Enterobacter aerogenes
Enterobacter cloacae
Klebsiella pneumoniae
Klebsiella spp. (other)
Pseudomonas aeruginosa
Serratia spp.
Morganella morganii

Gram-positive aerobes:

Staphylococcus aureus£
Streptococcus pneumoniae££

Gram-positive anaerobes:

Clostridium perfringens
Peptococcus spp.
Peptostreptococcus spp.

Gram-negative anaerobes:

Fusobacterium spp.

Inherently resistant organisms

Gram-positive aerobes:

Enterococci including Enterococcus faecalis and Enterococcus faecium
Listeria spp.

Gram-positive anaerobes:

Clostridium difficile

Gram-negative anaerobes:

Bacteroides spp. (many strains of Bacteroides fragilis are resistant).

Others:

Chlamydia spp.

Mycoplasma spp.

Legionella spp.

†S. aureus that is methicillin-susceptible are considered to have inherent low susceptibility to ceftazidime. All methicillin-resistant S. aureus are resistant to ceftazidime.

††S. pneumoniae that demonstrate intermediate susceptibility or are resistant to penicillin can be expected to demonstrate at least reduced susceptibility to ceftazidime.

+ High rates of resistance have been observed in one or more areas/countries/regions within the EU.

5.2 Pharmacokinetic properties

Absorption

After intramuscular administration of 500 mg and 1 g of ceftazidime, peak plasma levels of 18 and 37 mg/l, respectively, are achieved rapidly. Five minutes after intravenous bolus injection of 500 mg, 1 g or 2 g, plasma levels are 46, 87 and 170 mg/l, respectively. The kinetics of ceftazidime is linear within the single dose range of 0.5 to 2 g following intravenous or intramuscular dosing.

Distribution

The serum protein binding of ceftazidime is low at about 10%. Concentrations in excess of the MIC for common pathogens can be achieved in tissues such as bone, heart, bile, sputum, aqueous humour, synovial, pleural and peritoneal fluids. Ceftazidime crosses the placenta readily, and is excreted in the breast milk. Penetration of the intact blood-brain barrier is poor, resulting in low levels of ceftazidime in the CSF in the absence of inflammation. However, concentrations of 4 to 20 mg/l or more are achieved in the CSF when the meninges are inflamed.

Biotransformation

Ceftazidime is not metabolised.

Elimination

After parenteral administration plasma levels decrease with a half-life of about 2 h. Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80 to 90% of the dose is recovered in the urine within 24 h. Less than 1% is excreted via the bile.

Special patient populations

Renal impairment

Elimination of ceftazidime is decreased in patients with impaired renal function and the dose should be reduced.

Hepatic impairment

The presence of mild to moderate hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days, provided renal function was not impaired.

Elderly

The reduced clearance observed in elderly patients was primarily due to age-related decrease in renal clearance of ceftazidime. The mean elimination half-life ranged from 3.5 to 4 hours

following single or 7 days repeat BID dosing of 2 g IV bolus injections in elderly patients 80 years or older.

Paediatric population

The half-life of ceftazidime is prolonged in preterm and term neonates by 4.5 to 7.5 hours after doses of 25 to 30 mg/kg. However, by the age of 2 months the half-life is within the range for adults.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeat dose toxicity, genotoxicity, toxicity to reproduction. Carcinogenicity studies have not been performed with ceftazidime.

6. Pharmaceutical particulars

6.1 List of excipients

Not Applicable

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Ceftazidime is less stable in Sodium Bicarbonate Injection than other intravenous fluids. It is not recommended as a diluent.

Ceftazidime and aminoglycosides should not be mixed in the same giving set or syringe.

Precipitation has been reported when vancomycin has been added to ceftazidime in solution. It is recommended that giving sets and intravenous lines are flushed between administration of these two agents.

Ceftazidime is incompatible with aminophylline. There is a possible incompatibility with pentamide.

6.3 Shelf life

24 Months

6.4 Special precautions for storage

Store at temperature below 25 °C. Protect from light.

Reconstituted solution should be used immediately after preparation.

KEEP OUT OF REACH OF CHILDREN

6.5 Nature and contents of container

Each 20ml USP Type III vial is packed in a single mono carton along with package insert.

6.6 Special precautions for disposal and other handling

For single use. Discard any unused contents.

Instructions for reconstitution: See table for addition volumes and solution concentrations, which may be useful when fractional doses are required.

PREPARATION OF SOLUTION

Vial size	Route of Administration	Amount of Diluent to be added (ml)	Approximate Concentration (mg/ml)
1g	Intramuscular	3 ml	263
1g	Intravenous bolus	10 ml	91

Ceftazidime (at the given concentration) has been shown to be compatible with the following diluent solutions:-

Sodium Chloride 0.9%

Ringer Lactate Solution

Glucose 5%

Glucose 5% and Sodium Chloride 0.9%

Lidocaine Hydrochloride 1%

Water for Injection

All sizes of vials as supplied are under reduced pressure. As the product dissolves, carbon dioxide is released and a positive pressure develops. For ease of use, it is recommended that the following techniques of reconstitution are adopted.

1. Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
2. Shake to dissolve: carbon dioxide is released and a clear solution will be obtained in about 1 to 2 minutes.
3. Invert the vial. With the syringe plunger fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the head space. The withdrawn solution may contain small bubbles of carbon dioxide; they may be disregarded.

These solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids. Ceftazidime is compatible with the intravenous fluids listed above.

7. Marketing authorisation holder:

Sance Laboratories Private Limited

8. Marketing authorisation number(s) :

Date of renewal: 06520/08032/REN/2021

9. Date of first authorisation/renewal of the authorization

08/09/2021

10. Date of revision of the text

11/07/2023